Tectonic Therapeutic (TECX) Expected to Announce Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) is expected to be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Tectonic Therapeutic to post earnings of ($1.05) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 6:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last posted its earnings results on Thursday, August 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.09). On average, analysts expect Tectonic Therapeutic to post $-8 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Tectonic Therapeutic Price Performance

NASDAQ:TECX opened at $17.51 on Tuesday. The firm has a market cap of $327.61 million, a price-to-earnings ratio of -4.33 and a beta of 3.23. The company has a 50 day moving average price of $17.52 and a 200-day moving average price of $20.24. Tectonic Therapeutic has a 1-year low of $13.70 and a 1-year high of $61.07.

Institutional Investors Weigh In On Tectonic Therapeutic

Several institutional investors and hedge funds have recently added to or reduced their stakes in TECX. Millennium Management LLC boosted its stake in Tectonic Therapeutic by 726.4% during the 1st quarter. Millennium Management LLC now owns 237,938 shares of the company’s stock worth $4,214,000 after purchasing an additional 209,145 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Tectonic Therapeutic by 331.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 104,793 shares of the company’s stock worth $1,856,000 after purchasing an additional 80,483 shares during the last quarter. Jane Street Group LLC boosted its stake in Tectonic Therapeutic by 58.7% during the 1st quarter. Jane Street Group LLC now owns 47,145 shares of the company’s stock worth $835,000 after purchasing an additional 17,443 shares during the last quarter. Geode Capital Management LLC boosted its stake in Tectonic Therapeutic by 242.5% during the 2nd quarter. Geode Capital Management LLC now owns 272,257 shares of the company’s stock worth $5,411,000 after purchasing an additional 192,770 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Tectonic Therapeutic by 483.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,548 shares of the company’s stock worth $130,000 after purchasing an additional 5,426 shares during the last quarter. Institutional investors and hedge funds own 62.63% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Wednesday, October 8th. Truist Financial started coverage on shares of Tectonic Therapeutic in a report on Monday, July 21st. They set a “buy” rating and a $64.00 target price for the company. Wells Fargo & Company started coverage on shares of Tectonic Therapeutic in a research note on Monday, October 20th. They issued an “overweight” rating and a $101.00 price target on the stock. Oppenheimer started coverage on shares of Tectonic Therapeutic in a research note on Wednesday, September 3rd. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, Wall Street Zen cut shares of Tectonic Therapeutic from a “hold” rating to a “sell” rating in a research note on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Tectonic Therapeutic currently has an average rating of “Moderate Buy” and a consensus price target of $80.29.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.